Short Interest in ICU Medical, Inc. (NASDAQ:ICUI) Declines By 10.1%

ICU Medical, Inc. (NASDAQ:ICUI) was the target of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 831,100 shares, a decrease of 10.1% from the August 31st total of 924,500 shares. Based on an average trading volume of 337,000 shares, the short-interest ratio is presently 2.5 days. Currently, 3.7% of the shares of the company are short sold.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,552 shares of company stock worth $4,537,802. Corporate insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors have recently modified their holdings of the business. Scout Investments Inc. grew its stake in shares of ICU Medical by 16.3% in the first quarter. Scout Investments Inc. now owns 51,819 shares of the medical instruments supplier’s stock worth $5,463,000 after purchasing an additional 7,272 shares during the last quarter. Wakefield Asset Management LLLP acquired a new position in ICU Medical in the first quarter valued at $989,000. Vanguard Group Inc. lifted its holdings in ICU Medical by 14.8% in the fourth quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock valued at $243,438,000 after buying an additional 315,103 shares during the period. SG Americas Securities LLC lifted its holdings in ICU Medical by 441.7% in the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares during the period. Finally, Sei Investments Co. lifted its holdings in ICU Medical by 52.1% in the first quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock valued at $3,068,000 after buying an additional 9,793 shares during the period. Institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 0.0 %

Shares of ICU Medical stock traded down $0.01 during trading on Friday, hitting $174.47. The company’s stock had a trading volume of 177,791 shares, compared to its average volume of 280,425. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. ICU Medical has a 52 week low of $78.28 and a 52 week high of $181.87. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of -71.21 and a beta of 0.65. The stock has a 50-day moving average price of $154.77 and a two-hundred day moving average price of $124.01.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the previous year, the firm posted $1.58 earnings per share. ICU Medical’s revenue for the quarter was up 8.6% on a year-over-year basis. Equities research analysts anticipate that ICU Medical will post 3.76 EPS for the current fiscal year.

Analyst Ratings Changes

ICUI has been the topic of a number of research reports. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. KeyCorp boosted their target price on shares of ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Raymond James boosted their target price on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and an average price target of $149.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.